Physician profile

Bina Jain

Internal Medicine · Reading, PA

NPI 1437363009

$806.82

in general payments reported to CMS, 2019-2025

21 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbvie INC. $101.07 2020-2021
Biohaven Pharmaceuticals, INC. $74.07 2021
Novo Nordisk INC $72.19 2020-2021
Glaxosmithkline, LLC. $66.57 2019-2021
Astellas Pharma US INC $63.06 2019-2021
Lilly USA, LLC $62.71 2020-2021
Boehringer Ingelheim Pharmaceuticals, INC. $56.82 2020-2021
Astrazeneca Pharmaceuticals LP $50.45 2020-2021
Pfizer INC. $37.96 2020-2021
Otsuka America Pharmaceutical, INC. $35.66 2020-2021
Merck Sharp & Dohme LLC $27.58 2020-2021
Abbott Laboratories $24.96 2019
Ibsa Pharma INC. $24.85 2020
Sunovion Pharmaceuticals INC. $15.95 2021
Amgen INC. $14.79 2021
Show all 21 companies
CompanyGeneral paymentsYearsTop products
Sanofi-Aventis U.S. LLC $14.48 2020
Amarin Pharma, INC. $14.12 2020
Philips North America LLC $13.65 2020
Daiichi Sankyo INC. $12.06 2021
Biodelivery Sciences International, INC. $11.91 2020
Mannkind Corporation $11.91 2021

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Bina Jain

$806.82

in general payments reported 2019-2025

Years
2019-2021
Top company
Abbvie INC.

https://glasscript.com/doctor/338069/bina-jain

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.